title: Ciprofloxacin in primary prophylaxis of spontaneous bacterial peritonitis: a randomized, placebo-controlled study.
abstract: OBJECTIVE
  Low protein concentration in ascitic fluid has been identified as a risk factor for spontaneous bacterial peritonitis (SBP). Until now, primary prophylaxis has not been recommended in these patients. The aim was to investigate the efficacy of long-term administration of ciprofloxacin to prevent SBP.
  
  
  METHODS
  One hundred cirrhotic patients with <1.5 g/dl of total protein in ascitic fluid were randomized prospectively, in a double blind fashion to receive ciprofloxacin 500 mg/day (n=50) or placebo (n=50) for 12 months.
  
  
  RESULTS
  Baseline data were similar in both groups. In the ciprofloxacin group, SBP occurred almost four times less frequently than in the placebo group but it was not statistically significant. The probability of survival at 12 months was significantly higher in patients receiving ciprofloxacin (86% versus 66%) (p<0.04). SBP and sepsis were the most frequent causes of death in the placebo group whereas gastrointestinal bleeding was responsible for the most deaths in the ciprofloxacin group. The probability of remaining free of bacterial infections was higher in patients receiving ciprofloxacin (80% versus 55%) (p=0.05).
  
  
  CONCLUSIONS
  Patients with cirrhosis and low protein concentration in ascitic fluid are candidates to receive long-term prophylaxis to reduce the risk of infections and improve survival.
authors.affiliation: Unidad de Hígado, Hospital de Gastroenterología Dr. Bonorino Udaondo, Sección Hepatología, Avenida Caseros 2061, 1264 Buenos Aires, Argentina. fundhig@speedy.com.ar
authors.forename: Rubén
authors.initials: R
authors.lastname: Terg
authors.forename: Eduardo
authors.initials: E
authors.lastname: Fassio
authors.forename: Mónica
authors.initials: M
authors.lastname: Guevara
authors.forename: Mariano
authors.initials: M
authors.lastname: Cartier
authors.forename: Cristina
authors.initials: C
authors.lastname: Longo
authors.forename: Romina
authors.initials: R
authors.lastname: Lucero
authors.forename: Cristina
authors.initials: C
authors.lastname: Landeira
authors.forename: Gustavo
authors.initials: G
authors.lastname: Romero
authors.forename: Nora
authors.initials: N
authors.lastname: Dominguez
authors.forename: Alberto
authors.initials: A
authors.lastname: Muñoz
authors.forename: Diana
authors.initials: D
authors.lastname: Levi
authors.forename: Carlos
authors.initials: C
authors.lastname: Miguez
authors.forename: Raquel
authors.initials: R
authors.lastname: Abecasis
mesh_terms: D000328:Adult; D000368:Aged; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy* / Q000401:mortality; D002939:Ciprofloxacin / Q000627:therapeutic use*; D006801:Humans; D008875:Middle Aged; D010538:Peritonitis / Q000188:drug therapy* / Q000401:mortality
chemical_list: D000890:Anti-Infective Agents; D002939:Ciprofloxacin